References
Cannon, M.J., Schmid, D.S., and Hyde, T.B. (2010). Review of
cytomegalovirus seroprevalence and demographic characteristics
associated with infection. Rev Med Virol 20, 202-213.
Chen, D., Frezza, M., Schmitt, S., Kanwar, J., and Dou, Q.P. (2011).
Bortezomib as the first proteasome inhibitor anticancer drug: current
status and future perspectives. Curr Cancer Drug Targets11, 239-253.
Chui, A.J., Okondo, M.C., Rao, S.D., Gai, K., Griswold, A.R., Johnson,
D.C., Ball, D.P., Taabazuing, C.Y., Orth, E.L., Vittimberga, B.A., and
Bachovchin, D.A. (2019). N-terminal degradation activates the NLRP1B
inflammasome. Science 364, 82-85.
Cox, J., and Mann, M. (2008). MaxQuant enables high peptide
identification rates, individualized p.p.b.-range mass accuracies and
proteome-wide protein quantification. Nat Biotechnol 26,1367-1372.
Dolan, A., Cunningham, C., Hector, R.D., Hassan-Walker, A.F., Lee, L.,
Addison, C., Dargan, D.J., Mcgeoch, D.J., Gatherer, D., Emery, V.C.,
Griffiths, P.D., Sinzger, C., Mcsharry, B.P., Wilkinson, G.W.G., and
Davison, A.J. (2004). Genetic content of wild-type human
cytomegalovirus. J Gen Virol 85, 1301-1312.
El Helou, G., and Razonable, R.R. (2019). Letermovir for the prevention
of cytomegalovirus infection and disease in transplant recipients: an
evidence-based review. Infect Drug Resist 12, 1481-1491.
Fielding, C.A., Aicheler, R., Stanton, R.J., Wang, E.C., Han, S.,
Seirafian, S., Davies, J., Mcsharry, B.P., Weekes, M.P., Antrobus, P.R.,
Prod’homme, V., Blanchet, F.P., Sugrue, D., Cuff, S., Roberts, D.,
Davison, A.J., Lehner, P.J., Wilkinson, G.W., and Tomasec, P. (2014).
Two novel human cytomegalovirus NK cell evasion functions target MICA
for lysosomal degradation. PLoS Pathog 10, e1004058.
Fielding, C.A., Weekes, M.P., Nobre, L.V., Ruckova, E., Wilkie, G.S.,
Paulo, J.A., Chang, C., Suárez, N.M., Davies, J.A., Antrobus, R.,
Stanton, R.J., Aicheler, R.J., Nichols, H., Vojtesek, B., Trowsdale, J.,
Davison, A.J., Gygi, S.P., Tomasec, P., Lehner, P.J., and Wilkinson,
G.W. (2017). Control of immune ligands by members of a cytomegalovirus
gene expansion suppresses natural killer cell activation. Elife6.
Goodwin, C.M., Ciesla, J.H., and Munger, J. (2018). Who’s Driving? Human
Cytomegalovirus, Interferon, and NFκB Signaling. Viruses 10.
Griffiths, P., Baraniak, I., and Reeves, M. (2015). The pathogenesis of
human cytomegalovirus. J Pathol 235, 288-297.
Halenius, A., Gerke, C., and Hengel, H. (2015). Classical and
non-classical MHC I molecule manipulation by human cytomegalovirus: so
many targets—but how many arrows in the quiver? Cell Mol
Immunol 12, 139-153.
Hsu, J.L., Van Den Boomen, D.J., Tomasec, P., Weekes, M.P., Antrobus,
R., Stanton, R.J., Ruckova, E., Sugrue, D., Wilkie, G.S., Davison, A.J.,
Wilkinson, G.W., and Lehner, P.J. (2015). Plasma membrane profiling
defines an expanded class of cell surface proteins selectively targeted
for degradation by HCMV US2 in cooperation with UL141. PLoS
Pathog 11, e1004811.
Jackson, S.E., Mason, G.M., and Wills, M.R. (2011). Human
cytomegalovirus immunity and immune evasion. Virus Res157, 151-160.
Kim, Y.E., Lee, J.H., Kim, E.T., Shin, H.J., Gu, S.Y., Seol, H.S., Ling,
P.D., Lee, C.H., and Ahn, J.H. (2011). Human cytomegalovirus infection
causes degradation of Sp100 proteins that suppress viral gene
expression. J Virol 85, 11928-11937.
Kisselev, A.F., and Goldberg, A.L. (2001). Proteasome inhibitors: from
research tools to drug candidates. Chem Biol 8, 739-758.
Le-Trilling, V.T., and Trilling, M. (2015). Attack, parry and riposte:
molecular fencing between the innate immune system and human
herpesviruses. Tissue Antigens 86, 1-13.
Manicklal, S., Emery, V.C., Lazzarotto, T., Boppana, S.B., and Gupta,
R.K. (2013). The ”silent” global burden of congenital cytomegalovirus.Clin Microbiol Rev 26, 86-102.
Nathans, R., Cao, H., Sharova, N., Ali, A., Sharkey, M., Stranska, R.,
Stevenson, M., and Rana, T.M. (2008). Small-molecule inhibition of HIV-1
Vif. Nat Biotechnol 26, 1187-1192.
Nightingale, K., Lin, K.M., Ravenhill, B.J., Davies, C., Nobre, L.,
Fielding, C.A., Ruckova, E., Fletcher-Etherington, A., Soday, L.,
Nichols, H., Sugrue, D., Wang, E.C.Y., Moreno, P., Umrania, Y., Huttlin,
E.L., Antrobus, R., Davison, A.J., Wilkinson, G.W.G., Stanton, R.J.,
Tomasec, P., and Weekes, M.P. (2018). High-Definition Analysis of Host
Protein Stability during Human Cytomegalovirus Infection Reveals
Antiviral Factors and Viral Evasion Mechanisms. Cell Host Microbe24, 447-460.e411.
Nobre, L.V., Nightingale, K., Ravenhill, B.J., Antrobus, R., Soday, L.,
Nichols, J., Davies, J.A., Seirafian, S., Wang, E.C., Davison, A.J.,
Wilkinson, G.W., Stanton, R.J., Huttlin, E.L., and Weekes, M.P. (2019).
Human cytomegalovirus interactome analysis identifies degradation hubs,
domain associations and viral protein functions. Elife 8.
Patel, M., Vlahava, V.M., Forbes, S.K., Fielding, C.A., Stanton, R.J.,
and Wang, E.C.Y. (2018). HCMV-Encoded NK Modulators: Lessons From in
vitro and in vivo Genetic Variation. Front Immunol 9,2214.
Price, C.T., Al-Quadan, T., Santic, M., Rosenshine, I., and Abu Kwaik,
Y. (2011). Host proteasomal degradation generates amino acids essential
for intracellular bacterial growth. Science 334,1553-1557.
Reeves, M.B., Macary, P.A., Lehner, P.J., Sissons, J.G., and Sinclair,
J.H. (2005). Latency, chromatin remodeling, and reactivation of human
cytomegalovirus in the dendritic cells of healthy carriers. Proc
Natl Acad Sci U S A 102, 4140-4145.
Schreiner, S., and Wodrich, H. (2013). Virion factors that target Daxx
to overcome intrinsic immunity. J Virol 87, 10412-10422.
Sloan, E., Orr, A., and Everett, R.D. (2016). MORC3, a Component of PML
Nuclear Bodies, Has a Role in Restricting Herpes Simplex Virus 1 and
Human Cytomegalovirus. J Virol 90, 8621-8633.
Stanton, R.J., Baluchova, K., Dargan, D.J., Cunningham, C., Sheehy, O.,
Seirafian, S., Mcsharry, B.P., Neale, M.L., Davies, J.A., Tomasec, P.,
Davison, A.J., and Wilkinson, G.W. (2010). Reconstruction of the
complete human cytomegalovirus genome in a BAC reveals RL13 to be a
potent inhibitor of replication. J Clin Invest 120,3191-3208.
Tanaka, J., Ogura, T., Kamiya, S., Sato, H., Yoshie, T., Ogura, H., and
Hatano, M. (1984). Enhanced replication of human cytomegalovirus in
human fibroblasts treated with dexamethasone. J Gen Virol 65 ( Pt
10), 1759-1767.
Tavalai, N., Adler, M., Scherer, M., Riedl, Y., and Stamminger, T.
(2011). Evidence for a dual antiviral role of the major nuclear domain
10 component Sp100 during the immediate-early and late phases of the
human cytomegalovirus replication cycle. J Virol 85,9447-9458.
Tran, K., Kamil, J.P., Coen, D.M., and Spector, D.H. (2010).
Inactivation and disassembly of the anaphase-promoting complex during
human cytomegalovirus infection is associated with degradation of the
APC5 and APC4 subunits and does not require UL97-mediated
phosphorylation of Cdh1. J Virol 84, 10832-10843.
Weekes, M.P., Tan, S.Y., Poole, E., Talbot, S., Antrobus, R., Smith,
D.L., Montag, C., Gygi, S.P., Sinclair, J.H., and Lehner, P.J. (2013).
Latency-associated degradation of the MRP1 drug transporter during
latent human cytomegalovirus infection. Science 340,199-202.
Weekes, M.P., Tomasec, P., Huttlin, E.L., Fielding, C.A., Nusinow, D.,
Stanton, R.J., Wang, E.C.Y., Aicheler, R., Murrell, I., Wilkinson,
G.W.G., Lehner, P.J., and Gygi, S.P. (2014). Quantitative temporal
viromics: an approach to investigate host-pathogen interaction.Cell 157, 1460-1472.
Wiertz, E.J., Jones, T.R., Sun, L., Bogyo, M., Geuze, H.J., and Ploegh,
H.L. (1996). The human cytomegalovirus US11 gene product dislocates MHC
class I heavy chains from the endoplasmic reticulum to the cytosol.Cell 84, 769-779.